CAR T cell therapy targets key mutation driving rare blood cancers

CAR T cell therapy targets key mutation driving rare blood cancers. A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to new research led by UCL and University of Oxford researchers.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to new research led by UCL and University of Oxford researchers.

• Ponto de atenção: cell.
• Ponto de atenção: therapy.
• Ponto de atenção: targets.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.